Many cancer therapeutic vaccines have advanced to clinical testing. Unfortunately, most have not demonstrated success. Gliknik has taken learnings from that history and applied them to investigational vaccine candidate GL-0817.
The GL-2045 discovery program started when a family member of one of Gliknik’s founders needed IVIG, a synthetic human blood product used to treat disorders of the immune system or to boost immune response to serious illness.
Gliknik’s stradobody™ program for cancer has been supported by a competitively won contract with the National Cancer Institute.
For decades doctors thought a synthetic version of the human blood product, IVIG, couldn’t be made. Gliknik’s synthetic version of IVIG is heading for clinical trials.